Trexquant Investment LP Increases Stock Position in LivaNova PLC $LIVN

Key Points

• Trexquant Investment LP increased its stake in LivaNova PLC by 195.3%, owning approximately $11.79 million worth of shares after acquiring 198,546 additional shares in the first quarter.
• Institutional investors hold about 97.64% of LivaNova's stock, with significant acquisitions by firms such as Nuveen LLC and Hotchkis & Wiley Capital Management.
• LivaNova reported a quarterly EPS of $1.05, exceeding analysts' expectations, alongside a revenue of $352.50 million, marking a 10.6% year-over-year growth.

Trexquant Investment LP lifted its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 195.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 300,199 shares of the company's stock after purchasing an additional 198,546 shares during the quarter. Trexquant Investment LP owned 0.55% of LivaNova worth $11,792,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LIVN. UMB Bank n.a. boosted its holdings in shares of LivaNova by 340.5% in the 1st quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after purchasing an additional 647 shares in the last quarter. CWM LLC boosted its holdings in shares of LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after purchasing an additional 299 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of LivaNova by 415.4% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock worth $58,000 after purchasing an additional 1,184 shares in the last quarter. Central Pacific Bank Trust Division boosted its holdings in shares of LivaNova by 7.0% in the 1st quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after purchasing an additional 290 shares in the last quarter. Finally, Corton Capital Inc. purchased a new position in shares of LivaNova in the 4th quarter worth about $214,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Trading Up 1.7%

LIVN traded up $0.92 during midday trading on Friday, reaching $56.37. 472,571 shares of the company's stock traded hands, compared to its average volume of 774,202. The firm has a fifty day moving average of $47.53 and a two-hundred day moving average of $43.29. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -14.49 and a beta of 0.96. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. The business had revenue of $352.50 million during the quarter, compared to analyst estimates of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.LivaNova's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.93 EPS. On average, equities analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on LIVN. Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a report on Tuesday, May 20th. Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Barclays increased their target price on LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Finally, Robert W. Baird increased their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.